Biswas, A., Banerjee, S., Gart, E
The significant weight loss achieved with GLP-1 therapy varies by agent and dosewith semaglutide 2.4mg (Wegovy) achieving approximately 15% body weight reduction at 68 weeks, while liraglutide 3mg (Saxenda) typically produces 5-8% weight loss
Beyond glucose lowering, incretin-based therapies are increasingly positioned within the broader cardiometabolic framework, with emerging data supporting cardiovascular and renal protection, as well as effects on endothelial function, atherosclerosis, heart failure phenotypes, and chronic kidney disease progression
Retatrutide changes the equation entirely
This is one of the most important long-term questions to consider
How Klinic Works Embarking on a weight loss journey with Klinic is a seamless process: Step 1: Insurance Verification Start by filling out a brief intake form detailing your health history and insurance coverage